Short answer
UTAH MEDICAL PRODUCTS INC (UTMD) filed an 8-K current report with the SEC on April 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 99.1 (), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 contains UTMD financial results for the three months ended March 31, 2026.
UTAH MEDICAL PRODUCTS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Exhibit 99.1 contains UTMD financial results for the three months ended March 31, 2026
- Forward-looking statements address 2026 and beyond, adding management outlook alongside quarterly results
- Disclosure furnished under Item 2.02, making the exhibit the source for detailed figures and guidance
Item 99.1 ·
- Filing signed April 23, 2026 by Kevin L. Cornwell, Chief Executive Officer
- Signature confirms UTMD’s authorized submission of the 8-K to the SEC
Item EX-99.1 · Exhibit EX-99.1
- Q1 sales fell 10.2% to $8.722M, reflecting zero China-distributor and PendoTECH sales versus $857K combined year-earlier revenue
- Net income declined 14.4% to $2.604M and EPS 11.0% to $0.818, despite lower taxes and 125,265 fewer diluted shares
- Gross margin improved to 60.6% from 57.0%, but operating margin fell to 29.4% from 32.5% on higher litigation and healthcare costs
- Cash and investments reached $87.406M with no debt, supporting $989K dividends and continued share repurchases
- Management described results as consistent with previously announced 2026 projections, while cautioning quarterly comparisons may not represent full-year performance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UTAH MEDICAL PRODUCTS INC 8-K filings
Get the next UTMD 8-K as it lands
Follow UTMD for push alerts, or ask the research agent what this filing means.